Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PURSUIT-Induction; PURSUIT-SC
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Jun 2018 Results of individual participant data (IPD) pooled analysis of five trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-Aminosalicylates modifies clinical outcomes, were published in the American Journal of Gastroenterology.
    • 05 Feb 2014 Results have been published in Gastroenterology according to a Janssen media release. Results were also reported in the media release.
    • 16 Oct 2013 Post-hoc analysis for the association between patient reported outcomes (stool frequency and rectal bleeding ) and mucosal healing presented at the 21st United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top